01 Shift toward Earlier Stage Kidney Function Assessment The cystatin C testing market analysis shows an emphasis on identifying kidney function changes. This is moving clinical assessment toward more detailed evaluation across different stages of chronic kidney disease. This change is broadening the role of additional kidney function biomarkers in clinical evaluation and creating greater scope for point-of-care (POCT) testing alongside conventional assessments.
02 Integration of Combined Kidney Function Biomarkers The integration of multiple kidney function biomarkers is shifting assessment from creatinine-only measurement toward combined creatinine and cystatin C evaluation. Current NIDDK guidance states that the combined creatinine cystatin C equation provides greater accuracy than serum creatinine alone and is particularly relevant when eGFR is near critical decision points such as drug dosing or kidney transplant evaluation. This clinical shift strengthens the role of cystatin C as a complementary biomarker and supports its incorporation into a more comprehensive GFR assessment.
01 Supply chain disruptions are expected to have a moderate impact on the cystatin C testing market share, given its direct exposure to fluctuations in assay reagents, calibrators, controls, analyzer components, laboratory consumables, and transportation costs. The market is expected to have a K-shaped recovery as large diagnostic companies with diversified reagent portfolios and established distribution networks can stabilize operations faster, while smaller laboratories and suppliers with limited procurement flexibility may face longer delays. The market is expected to grow at a CAGR of 7.39%, but supply chain constraints could approximately lower this by 1.5 percentage points, resulting in short-term growth of around 5.89%. As supply conditions normalize through improved reagent and component availability and replenished laboratory inventories, the cystatin C testingmarket growth is expected to gradually return to 7.39%.
01 The cystatin C testing market forecasts investments directed toward advanced kidney-function diagnostics, automated laboratory testing platforms, and biomarker-based clinical testing capabilities to support earlier detection and monitoring of chronic kidney disease and acute kidney injury. Gentian reported that it was continuing to invest in Cystatin C, particularly in the US, including infrastructure and additional activities with partners under its “Accelerate Cystatin C” initiative.
01 Chronic Kidney Disease Burden and Adoption of Precise Renal Assessment Drive Cystatin C Testing Market The projected increase in chronic kidney disease burden is expanding the number of patients requiring regular kidney function testing, increasing the need for additional biomarkers that can provide more reliable renal function information. The World Health Organization projects kidney disease to become the fifth leading cause of death globally by 2050, indicating a booming future population requiring CKD detection, monitoring, and risk assessment.The clinical reliance on more accurate GFR estimation is further supporting demand for cystatin C testing, particularly when creatinine-based assessment may be affected by muscle mass, age, or other non-renal factors. Recent clinical evidence indicates that cystatin C-inclusive equations can improve GFR estimation and support CKD staging, risk assessment, and medication dosing, creating greater clinical demand for cystatin C measurement alongside conventional creatinine testing.
01 Higher Testing Costs and Specialized Laboratory Requirements Restrain Market Expansion Higher testing costs compared with conventional creatinine testing increase the financial burden on laboratories, healthcare providers, and patients. The additional expense can reduce the use of cystatin C testing in routine kidney function assessment, particularly in cost-sensitive healthcare settings. These cost differences can slow broader adoption and limit market expansion.The dependence on specialized laboratory equipment and reagents increases the infrastructure and operational requirements for cystatin C testing. Limited access to suitable analyzers, trained personnel, and consistent reagent supplies can restrict testing availability across smaller or resource-limited laboratories. Such limitations can reduce test accessibility and slow the adoption of cystatin C testing.
01 Development of Automated Assay Platforms and Use of Cystatin C Measurements in Medication Management Applications Offer Growth Opportunities The development of automated and high-throughput assay platforms is creating opportunities to improve the efficiency of cystatin C testing in clinical laboratories. Integration with automated analyzers can reduce manual processing, support consistent workflows, and allow laboratories to handle larger testing volumes. Higher focus on assay standardization and improved analytical performance can also strengthen confidence in test results, creating opportunities for diagnostic companies to develop more extensible cystatin C testing solutions.The increasing use of cystatin C measurements in medication management applications is creating opportunities for testing providers to develop solutions linked to renal drug dosing decisions. Cystatin C-based GFR estimates can provide additional information about when kidney function needs to be assessed for medications with renal dosing considerations. Diagnostic companies can develop reporting tools and laboratory solutions that connect cystatin C results with clinical decision support workflows. This can expand the practical applications of cystatin C testing beyond routine kidney function assessment.
01 Complex Clinical Standardization and Limited Awareness among Healthcare Professionals Hinder Advanced Testing Practices Variations in cystatin C assay calibration, reference ranges, and testing practices can make results less consistent across laboratories. This lack of standardization can complicate clinical interpretation and reduce confidence in using cystatin C results for routine kidney function assessment, slowing broader adoption.Limited awareness among healthcare professionals about the clinical applications and interpretation of cystatin C can reduce test ordering. Continued reliance on familiar creatinine-based assessments may limit integration of cystatin C testing into routine clinical workflows and restrict market expansion.